http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 11 Sep 2026 11:47:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Barinthus+Biotherapeutic+++++++++++++++Filed+by%3A+Oxford+Science+Enterprises+plc/27051861.html si-local-file:///var/storage/secattach/20260911/27051861.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Barinthus+Biotherapeutic+++++++++++++++Filed+by%3A+Oxford+Science+Enterprises+plc/27051861.html Fri, 11 Sep 2026 11:47:00 -0400 BRNS http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Barinthus+Biotherapeutic++For%3A+Sep+09++Filed+by%3A+Oxford+Science+Enterprises+plc/27051630.html si-local-file:///var/storage/secattach/20260911/27051630.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Barinthus+Biotherapeutic++For%3A+Sep+09++Filed+by%3A+Oxford+Science+Enterprises+plc/27051630.html Fri, 11 Sep 2026 11:01:00 -0400 BRNS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Barinthus+Biotherapeutic++For%3A+Aug+24/26970341.html si-local-file:///var/storage/secattach/20260825/26970341.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Barinthus+Biotherapeutic++For%3A+Aug+24/26970341.html Tue, 25 Aug 2026 06:05:00 -0400 BRNS O.26439737 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Barinthus+Biotherapeutic++For%3A+Aug+24/26970341.html si-local-file:///var/storage/secattach/20260825/26970341.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Barinthus+Biotherapeutic++For%3A+Aug+24/26970341.html Tue, 25 Aug 2026 06:05:00 -0400 BRNS O.26439737 http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Press+Releases/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html <ul type="disc"><li style="text-align:justify;"><em>Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement</em></li><li style="text-align:justify;"><em>Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open</em></li><li style="text-align:justify;"><em>Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog</em><br/><br/></li></ul> <p>GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. http://www.streetinsider.com/Globe+Newswire/Barinthus+Bio+Provides+Update+on+Proposed+Combination+with+Clywedog+Therapeutics/26969456.html Mon, 24 Aug 2026 18:57:00 -0400 A.50216776 A.50216781 A.50216956 BRNS O.26439737 O.29783969 O.40934882 O.54729495 http://www.streetinsider.com/Earnings/Barinthus+Biotherapeutics+plc+%28BRNS%29+Tops+Q2+EPS+by+2c/26880085.html <p>Barinthus Biotherapeutics plc (NASDAQ: BRNS) reported Q2 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28).</p><p>For earnings history and earnings-related data on Barinthus Biotherapeutics plc (BRNS) <a href="http://www.streetinsider.com/ec_earnings.php?q=BRNS">click here</a>.</p> http://www.streetinsider.com/Earnings/Barinthus+Biotherapeutics+plc+%28BRNS%29+Tops+Q2+EPS+by+2c/26880085.html Thu, 06 Aug 2026 08:49:49 -0400 BRNS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Barinthus+Biotherapeutic++For%3A+Aug+06/26880087.html si-local-file:///var/storage/secattach/20260806/26880087.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Barinthus+Biotherapeutic++For%3A+Aug+06/26880087.html Thu, 06 Aug 2026 08:49:00 -0400 BRNS O.26439737 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Barinthus+Biotherapeutic++For%3A+Aug+06/26880087.html si-local-file:///var/storage/secattach/20260806/26880087.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Barinthus+Biotherapeutic++For%3A+Aug+06/26880087.html Thu, 06 Aug 2026 08:49:00 -0400 BRNS O.26439737 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Barinthus+Biotherapeutic++For%3A+Jun+30/26880065.html si-local-file:///var/storage/secattach/20260806/26880065.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Barinthus+Biotherapeutic++For%3A+Jun+30/26880065.html Thu, 06 Aug 2026 08:47:00 -0400 BRNS O.26439737 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Barinthus+Biotherapeutic++For%3A+Jun+30/26880065.html si-local-file:///var/storage/secattach/20260806/26880065.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Barinthus+Biotherapeutic++For%3A+Jun+30/26880065.html Thu, 06 Aug 2026 08:47:00 -0400 BRNS O.26439737